Objectives
(1) To obtain information that would enable the American Rheumatism Association (or other group) to decide whether a controlled comparison of various treatments of rheumatoid arthritis is feasible, and if so, how it could best be planned;
(2) To ascertain the experience of certain clinics, during a certain time period, in the treatment of rheumatoid arthritis with cortisone; (3) To look for differences in response that might appear to be related to certain features in the patients or to the mode of treatment; (4) To look for differences between the reports of different clinics regarding outcome and to seek for hints of possible explanations; (5) To form an impression of the facilities of the clinics and of their suitability for possible co-operation in a subsequent controlled comparison of different treatments.
Method
Early in the study the following criteria for admitting patients to the project were agreed on:
(1) Patients must have straightforward rheumatoid arthritis of peripheral joints.
(2) Cortisone must have been the main therapeutic agent used.
(3) The arthritis must have been present for at least 6 months before the administration of cortisone.
(4) Only patients would be included who had been observed by the participating physician for a period of at least one year since the initiation of cortisone, and the patient must have received cortisone continuously,* in doses not smaller than 15 mg. daily, with the following exceptions:
(a) dosage stopped because of sustained remission; (b) dosage stopped because of toxicity; (c) dosage reduced or discontinued temporarily for observation of patient's response; (d) dosage discontinued because of inadequate benefit to the patient.
The criteria adopted by the American Rheumatism Association (Steinbrocker, Traeger, and Batterman, 1949) In order to make the collection of data as comparable as possible, special printed forms were adopted for the recording of information (opposite).
Limitations of the Method.-From the outset it was clear that a retrospective analysis of this sort would have certain drawbacks; and other limitations became apparent as the study progressed. Such an analysis, for example, does not permit detailed recording of new observations during the study, but must make use of data already recorded by clinicians who made their original entries with no idea that they would subsequently become part of a statistical investigation. Furthermore, many of the data had been recorded on the original clinic charts several years before the study began and the workers who transferred these data to the official forms (Figure) were not in many instances those who had recorded the original observations. This difficulty was made greater by the fact that the stage and class of disease and the grade of response were recorded at clinic visits in only a few clinics, so that observers who knew the patients only slightly, if at all, often had to translate clinic notes into terms of the official criteria.
It should constantly be borne in mind that this study was primarily designed to ascertain the amount and kind of information that was available. It did not, therefore, meet the requirements of a definitive study. These requirements and a discussion of the limitations of the survey method are presented in the companion article (Mainland, 1955) which immediately follows this report. In the analysis, attention was confined to those statements and figures that had the appearance of being most reliable. If, however, it had been possible to make, at each clinic, a proper study of the numerous factors influencing the figures and other statements that were received, some of the estimates and inferences presented here might have been different.
The Sample
Forms were collected for a total of 608 patients from the various clinics, of which 62 had to be eliminated because of incompleteness or obvious unreliability, leaving 546 which form the basis of this analysis. The question of bias in selection of patients was obviated by including only patients from those clinics which submitted data on their total patient population which met the criteria. The patients all had been under observation for at least one year since the start of cortisone therapy and many had been under treatment and observation for longer periods between 1949, when cortisone first became available, and May 1, 1953, the closing date for submitting forms for inclusion in the analysis. Some patients had been under treatment throughout this period, but others only during the early or later parts of it. Clearly, it was a period of change in methods of selecting patients for cortisone and in schedules of dosage. (p. 326) . These were considered essential to ensure the inclusion of only genuine cases of rheumatoid arthritis. However, the requirements themselves introduced several difficulties. For example, a patient in whom cortisone had been tried previously and found either ineffective or "toxic" would probably not get into the series.
Age at Onset of Disease.-Four patients were under 5 years of age at the onset of their disease, and three patients were over 80. In only slightly more than 4 per cent. was the age at onset of disease under 15. The frequency of first episodes rose rapidly from age 15 to age 30, remained high to age 60, and then fell rapidly. Fully three-quarters of the patients had experienced the onset of disease between the ages of 25 and 60 years.
It is not possible to determine accurately the age incidence of a disease from data such as these, because one does not know the number of persons at a given age in the general population from which these patients were drawn who might have attended these clinics had they been attacked. Therefore, we have chosen not to show the foregoing figures, and those in the following paragraphs, in graph form lest they appear to possess an accuracy which would be unwarranted.
Age Of these, 29 (5 per cent. of the total) had died, and 85 (16 per cent. of the total) had been lost to the study for a variety of reasons: about one-quarter because of dissatisfaction resulting from "toxicity" or lack of benefit, about one-third because of transfer to care by other physicians or movement to another community, and about one-fifth because of failure to co-operate. It is probably safe to assume that, save for the ten who moved to other communities, most of these patients were not satisfied with the results.
Table I (opposite) shows certain data on the 29 patients who died. Probably some of these deaths were related to the cortisone therapy, whereas such a relationship appears most unlikely in others. However, information regarding all possible untoward effects of cortisone is still too meagre to decide which of these deaths were and which were not influenced by therapy. Dosage.-During the first few weeks or months of cortisone therapy, the dose used is relatively large in many clinics and rather wide variations in the amount given are frequent from week to week. In analysing the dosage schedules employed, therefore, the first 3 months of treatment were excluded. In 43 per cent. of the patients the average daily dose after the third month of treatment was not more than 50 mg.; conversely, in 57 per cent. it was more than 50 mg. Since the more seriously ill patients would be expected to require the larger doses, it was not surprising to find that those taking more than 50 mg. daily tended to receive cortisone longer than those taking 50 mg. or less. Conversely, it was not unexpected to find that considerably more of the patients receiving the smaller doses went into remission (23 per cent.) than of those receiving the larger doses (7 per cent.). Undesirable Occurrences during Cortisone Therapy.-The untoward events in patients receiving cortisone are usually referred to as "effects" of treatment. For the purposes of this report it has seemed preferable to call these "occurrences", because it is not always possible to be certain whether or not the hormone was the cause. In most instances, however, it is reasonable to suppose that these undesirable occurrences were, in fact, related to the therapy.
For purposes of this discussion the undesirable occurrences were separated into those considered of major significance and those of minor importance. This is, of course, an arbitrary distinction and not all readers will agree on the category into which the specific occurrences are placed. Notably, for example, many would include glycosuria among the minor incidents, and others might consider excessive fatigability a major symptom of danger. Table II lists the "major" undesirable occurrences. It will be noted that almost half of the patients exhibited one or more and that, as would be expected, the incidence was greater in patients receiving more than 50 mg. cortisone daily. Table III lists the "minor" undesirable occurrences. Again, the incidence was greater in the group receiving more than 50 mg. cortisone daily, but, as in the case of the "major" occurrences, some rences with the exception of pathological fractures and, possibly, of peptic ulcer. Pathological fractures, as would be expected in view of the increase in osteoporosis in post-menopausal women and in elderly males, were found more often in the older patients (the actual figures being none under age 20, 0 6 per cent. in the 20 to 44 year age group, 3 3 per cent. in the 45 to 64 year age group, and 9 8 per cent. in the 51 patients over 65). Conversely, peptic ulcer was noted in 9 3 per cent. of patients between 20 and 44 years of age, in 6-3 per cent. of those between 45 and 64, and in only 2 per cent. of those over the age of 64. These figures do not necessarily represent the true incidence of such occurrences in patients receiving cortisone.
Taking the major undesirable occurrences as a whole, it is of interest to note that, save for the patients below the age of 20 (only 4 per cent. affected), the rates among the patients in the three older age groups were almost identical-50, 46, and 49 per cent. respectively. Effect of Treatment on Nodules and Psoriasis.-Rheumatoid subcutaneous nodules were recorded as present in 159 patients (29 per cent.). These increased in number or size or both during treatment in 21, and remained unchanged in 79; they decreased in 37 patients, but disappeared in only nine. There was no record of the result in the remaining thirteen patients. Thus, there appeared to be no relationship between the course of the nodules and the administration of cortisone.
Psoriasis was reported in 27 (5 per cent.) of the 546 patients. As in the case of nodules, there appeared to be no relationship between cortisone therapy and the course of the cutaneous lesions.
Effect of Treatment on Arthritis
The motivating purpose of the entire study, of course, was to see what might be learned from the various clinics regarding the effects of cortisone on the articular and systemic manifestations of rheumatoid arthritis.
Table IV (opposite) summarizes the grade of improvement in 546 patients at the end of observation if they were still on cortisone, or at the time cortisone was stopped. The time that cortisone was stopped was taken for purposes of recording as the last date before stopping cortisone on which observations of grade of improvement were reported on the survey form. Since the latter was done at 3-monthly intervals, this length of time would be the maximum possible interval between the date of the observation of grade of improvement and the date of stopping cortisone. It should be pointed out that the grades of improvement noted correspond to different periods of treatment for different individuals, these intervals being in some cases as short as a few weeks and in other cases as long as 36 months. Also, since cortisone was stopped because of toxicity in the case of some patients, the grades of improvement given apply in a proportion of the cases to patients who at the time of evaluation were exhibiting toxic reactions to cortisone serious enough to require stopping the drug. This, however, would not be expected to influence the grade of improvement. Finally, it is likely that at the time of the last evaluation before stopping cortisone, the dosage was being tapered off in a number of the patients; so that even though cortisone had not been stopped, it has been reduced in dosage sufficiently to render these patients susceptible to relapse of symptoms.
It is readily apparent from the Table that the greatest improvement occurred in those patients whose disease was less far advanced.
Intercinic Variations.-It has been intended to subject the data from the total group of patients to more detailed analysis. However, appraisal of the forms submitted for the individual patients revealed such wide variations for the different clinics that such an approach was invalid. Total .100 100 100 100 100 100 100 100 100 100 100 100 100 100 * Inadequate Benefit = Cortisone stopped permanently because it was judged to confer inadequate benefit, or patient became worse.
occurrence being only slightly greater than 0-001 (by the x2 contingency test). In order to learn whether there was any obvious factor that might help account for these differences, the data in Table  V were analysed from the following standpoints:
( For each of these eleven items a relationship with the performance index (percentages in Grades 1 and 2) of the same clinic at 12 months was sought by dot diagram, and if the diagram showed any possibility of a relationship a correlation coefficient was calculated. The method is crude, but, with one exception, there was no suggestion of a correlation. The one exception was a negative correlation (rank correlation coefficient -0 53) between the percentage in Grades 1 and 2 and the average number of joints involved at the start of cortisone therapy. That is, the smaller the average number of joints involved per patient, the higher was the percentage of patients in the more favourable groups.
The possibility was also borne in mind that in some clinics the patients may have had more "active" rheumatoid arthritis, or arthritis less susceptible to change by any form of therapy. For example, some clinics may have chosen for cortisone therapy chiefly patients who had responded poorly to other forms of treatment, whereas in other clinics cortisone may have been the first therapeutic agent selected. Unfortunately, differences of this type are not necessarily reflected in stage and class of disease and hence are not readily distinguished in the forms from which the statistical analyses were derived.
In spite of these possible factors, no simple explanations were found which would satisfactorily account for all the variations between clinics. A very plausible suggestion is that the differences lay largely in the interpretations of the various clinic physicians-differences in interpretation of the criteria of stage and class of disease and of grade of response, in judgment as to severity of disability, undesired occurrences, and the like. The incidence of unsatisfactory benefit plus "toxic effects" sufficient to require stopping cortisone reported by the various clinics illustrates this point well. As shown in However, the number of contributions from many of the clinics had become so small by that time that it would be unwise to draw conclusions from the 30-month data, which are not included in Table VI. As regards the fairly steady ratio of 3: 7 during the 2-year period, inspection of the raw data revealed that this was not due to any two-way flow between the favourable and unfavourable groups, but mostly to a tendency for patients to remain in one or the other of these broad groups. patients. However, the limitations of the method of study and the small number of patients do not justify a firm conclusion. Discussion In addition to the aim of obtaining information about the course of rheumatoid arthritis in patients under treatment with cortisone, an important purpose of this study was to learn whether a controlled comparison of various forms of treatment of this disease is feasible. In this connexion the most important feature was probably the revelation of the great differences in the data of the different clinics. For evaluation of cortisone therapy it has sometimes been proposed that a comparison be made of a cortisone-treated series of patients with a series treated before the days of cortisone. This "previous series" method is always perilous, and how perilous it may be is well illustrated by the present survey, where large differences between cortisone-treated series are revealed.
A co-operative scheme of a "forward-moving" clinical trial, e.g. comparison of cortisone and salicylates, for example, would doubtless reduce the interclinic differences by standardization of methods and criteria; but it is improbable that it would remove serious interclinic differences entirely. Therefore, it would be unrealistic to expect that direct pooling of the data from all the participating clinics would be permissible. Samples of the present size might well be adequate to show the superiority of one or another treatment; but even the largest individual samples in the present series would not give precise estimates of the benefits of any one treatment in any one clinic.
The large number of patients in this survey who received other agents as concomitant therapy, and the urgent desire of many patients to receive cortisone, suggests that there might be considerable difficulty in obtaining sufficient participants for an adequate co-operative, standardized, controlled trial in clinics in the United States. From the quality of the data, however, it appears probable that it would be possible to select certain clinics or physicians as appropriate participants in a controlled clinical trial or in some other type of study.
Summary and Conclusions
A statistical analysis has been made of the course of rheumatoid arthritis in a group of patients treated with cortisone in 29 co-operating clinics and observed for 1 to 3 years between 1949 and 1953. Certain of the data reported were derived from the entire sample of 546 patients, whereas others which required more detailed analysis were derived from a smaller sample of approximately half that number from thirteen clinics which submitted the largest individual samples.
The survey was designed primarily to reveal the amount and kind of information available throughout the country and did not meet the requirements of a definitive study, but the estimates and inferences are based on those statements and figures that had the appearance of being the most reliable.
In three-quarters of the patients the onset of disease had occurred between the ages of 25 and 60 years. Females comprised 63 per cent. of the group and males 37 per cent.
In roughly 25 per cent. of the patients, rheumatoid arthritis had been present for less than 4 years, in 50 per cent. less than 8 years, and in 25 per cent. more than 12 years.
Most of the patients had received therapy before the study began, and some also received concomitant therapy with agents other than cortisone during the period of the study; but valid conclusions as to the benefit of such treatments could not be drawn.
At the end of the period of study, 432 of the 546 patients were still under observation, and of these 60 per cent. were still receiving cortisone. Of the other 114 patients, 29 (5 per cent.) had died, and 85 (16 per cent.) had been lost to the study.
Undesirable occurrences of major significance were seen in 46 per cent. of the 546 patients, and minor undesirable occurrences in 72 per cent.
Rheumatoid subcutaneous nodules were present in 29 per cent., and psoriasis in 5 per cent. No significant relationship was found between the course of these lesions and treatment with cortisone.
Wide differences in the progress of patients under cortisone were reported by the various clinics. These great differences which appeared to arise chiefly from differences in interpretation and judgment on the part of the various clinic physicians, made necessary special statistical treatment of the data in order to arrive at justifiable conclusions.
Among the patients more severely affected by the disease (Stages 3 and 4 when the study began), the ratio of favourable to unfavourable results at the end of 2 years was 3: 7 in terms of grade of response, and 4: 6 in terms of improvement in functional class. In the more mildly affected patients (Stages 1 and 2 when the study began), the proportion of favourable results was larger. In all groups improvement was more favourable in terms of functional class than in terms of grade of response (as defined by the American Rheumatism Association; Steinbrocker and others, 1949) .
The limitations of this type of therapeutic survey are discussed more fully by Mainland (1955 El primer objeto de esta investigation fue el averiguar el tipo y la cantidad de informaci6n disponible en el pais sin crear condiciones para un estudio de precision, pero los calculos y las deducciones aqui se basan sobre informes y cifras que ofrecen la mayor apariencia de exactitud.
En los tres cuartos de los sujetos la enfermedad habia empezado entre la edad de 25 y 60 afios. El grupo comprendio un 63% de mujeres y un 37% de hombres.
En cerca de 25% de los enfermos la artritis reumatoide habia existido desde menos de 4 anos, en 50% desde menos de 8 afnos y en un 25% desde menos de 12 afios.
La mayoria de los enfermos obtuvo tratamiento antes de empezar esta investigaci6n; algunos recibieron, ademAs de la cortisona, otra terapia durante el periodo de investigaci6n; no se puede sin embargo sacar conclusiones validas respecto al beneficio de tales tratamientos.
Al cabo de la investigaci6n, de los 546 enfermos, 432 encontrabanse todavia bajo observacion y el 60% de ellos seguia recibiendo cortisona. De los demas 114, 25 (5%) murieron y 85 (16%) encontraronse por varias razones fuera de la investigaci6n.
Ocurrencias nocivas mayores se observaron en el 46% y menores en el 72%.
N6dulos reumaticos subcutaneos se vieron en un 29% y psoriasos en un 5%. No se not6 relaci6n significative entre la evolucion de estas lesiones y el tratamiento con la cortisona.
Al comparar los informes de varias clinicas se observaron grandes diferencias en el progreso de los enfermos tratados con cortisona. Estas diferencias debidas principalmente a la interpretaci6n y al juicio de los medicos de las clinicas, exigieron una elaboraci6n estadistica especial de los datos para poder llegar a conclusiones justificables.
En los enfermos graves (periodo 3 y 4 al tiempo de empezar la investigaci6n) al cabo de 2 anos la proporcion de los resultados favorables y desfavorables fue de 3: 7 segun los criterios de la respuesta terapeutica graduada y de 4: 6 desde el punto de vista de la mejoria funcional. En los enfermos benignos (periodo 1 y 2 al empezar la investigation) la proporcion de los resultados favorables fue mayor. En todos los grupos el criterio funcional indico resultados mas favorables que el criterio de la reacci6n terapeutica graduada (definidos por la American Rheumatism Association; Steinbrocker y col., 1949).
Se discuten mAs detalladamente las limitaciones de tal investigation terapeutica en enfermedades del tipo de arthritis reumatoide en el articulo siguiente (Mainland, 195 5) .
